Tirzepatide (Mounjaro) is a GIP analogue that is used to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.
Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, which is believed to increase insulin secretion and improve blood sugar control. A meta-analysis showed that over one year of clinical use, tirzepatide was superior to other antidiabetic medications, such as dulaglutide, semaglutide, degludec, and insulin glargine, in terms of glycemic efficacy and obesity reduction.
Impressive weight loss results
The SURMOUNT-1 clinical trial by Eli Lilly and Company has shown promising results for tirzepatide as a weight loss treatment. The study, which enrolled 2,539 participants, showed that those taking tirzepatide (5 mg, 10 mg, or 15 mg) achieved significantly greater weight loss compared to those taking placebo.
Comparing weight loss results
The results of a phase 3 clinical trial showed that a high dosage of tirzepatide produced superior weight loss results compared to any other available medication. On average, patients in the trial lost 22.5% of their body weight, which equates to approximately 52 pounds. The majority of participants in the trial had a body mass index (BMI) of 30 or higher. In comparison, other weight loss drugs such as Wegovy and Saxenda resulted in a weight reduction of approximately 15% and 5%, respectively.
More on Mounjaro weight loss results
Tirzepatide met both primary endpoints of superior mean percent change in body weight and greater percentage of participants achieving a body weight reduction of at least 5% compared to placebo. The study also met all key secondary endpoints. Participants taking tirzepatide 5 mg lost an average of 16.0% (35 lb. or 16 kg) of their body weight, while those taking 10 mg lost 21.4% (49 lb. or 22 kg) and those taking 15 mg lost 22.5% (52 lb. or 24 kg). 89% of those taking 5 mg tirzepatide and 96% of those taking 10 mg or 15 mg achieved at least 5% body weight reduction, compared to 28% of those taking placebo.
In addition, 55% of those taking 10 mg and 63% of those taking 15 mg tirzepatide achieved at least 20% body weight reduction, compared to just 1.3% of those taking placebo. 32% of those taking 5 mg tirzepatide also achieved at least 20% body weight reduction in a secondary endpoint not controlled for type 1 error. The mean baseline body weight of participants was 231 lb. (105 kg). The most common side effects include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain.
What are GLP1-a analogues
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood sugar control. After a person has eaten, these hormones are secreted by cells of the intestines and in turn cause the secretion of insulin. Tirzepatide is a GIP-analogue that activates both the GLP-1 and GIP receptors, leading to improved blood sugar control.
FDA approval (diabetes)
Tirzepatide was approved for medical use in the United States in May 2022, in the European Union in September 2022, in Canada in November 2022, and in Australia in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. It is currently being fast tracked for weight loss indication given the above.
Off label use for weight loss
Given stellar weight loss results in the diabetes trial, this medication is being studied and fast tracked for weight loss. However, many doctors started prescribing this medication as an off label use for weight loss including by W8MD doctors given the best in the industry weight loss results.
Tirzepatide is indicated to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise.
Tirzepatide should not be used in people with a personal or family history of medullary thyroid cancer or in people with multiple endocrine neoplasia syndrome type 2.
Preclinical, phase I, and phase II clinical trials indicated that tirzepatide exhibits adverse effects similar to those of other established GLP-1 receptor agonists, such as dulaglutide. These effects occur largely within the gastrointestinal tract. The most frequently observed are nausea, diarrhea and vomiting, which increased in incidence with the dosage amount (i.e. higher likelihood the higher the dose). The number of patients who discontinued taking tirzepatide also increased as dosage increased, with patients taking 15 mg having a 25% discontinuation rate vs 5.1% for 5 mg patients and 11.1% for dulaglutide. To a slightly lesser extent, patients also reported reduced appetite. Other side effects reported were dyspepsia, constipation, abdominal pain, dizziness and hypoglycaemia.
Tirzepatide is an analogue of gastric inhibitory polypeptide (GIP), a human hormone that stimulates the release of insulin from the pancreas. Tirzepatide is a linear polypeptide of 39 amino acids that has been chemically modified by lipidation to improve its uptake into cells and its stability to metabolism. It completed phase III trials globally in 2021.
Mechanism of action
Tirzepatide has a greater affinity to GIP receptors than to GLP-1 receptors, and this dual agonist behavior has been shown to produce greater reductions of hyperglycemia compared to a selective GLP-1 receptor agonist. Signaling studies reported that tirzepatide mimics the actions of natural GIP at the GIP receptor. However, at the GLP-1 receptor, tirzepatide shows bias towards cAMP (a messenger associated with regulation of glycogen, sugar and lipid metabolism) generation, rather than β-arrestin recruitment. This combination of preference towards GIP receptor and distinct signaling properties at GLP-1 suggest this biased agonism increases insulin secretion. Tirzepatide has been reported to increase levels of adiponectin, an adipokine involved in the regulation of both glucose and lipid metabolism, with a maximum increase of 26% from baseline after 26 weeks, at the 10 mg dosage.
Need a doctor to prescribe Mounjaro?
W8MD physicians, with over 12 years of experience in the field of obesity medicine, are familiar with Mounjaro and can prescribe the medication when appropriate. As we accept most health insurances with the program fee of just $50.00 above insurance, we are one of the most cost effective way to get Mounjaro prescriptions in New York City, New Jersey, Pennsylvania and other areas.
W8MD Weight Loss, Sleep & Medspa Centers
W8MD Weight Loss, Sleep & Medspa Centers is a network of medical centers located in New York, Pennsylvania, New Jersey and surrounding areas that provide comprehensive care for weight loss, sleep disorders, and aesthetic treatments.
W8MD has several locations for your convenience:
- Philadelphia, PA: Philadelphia medical weight loss, sleep and medspa: 1718 Welsh Road, 2nd Floor, Philadelphia, PA 19115. Contact: (215)676-2334'
- Wayne, PA: King of Prussia medical weight loss, sleep and medspa: 175 Strafford Avenue, Ste 1, lower level, Wayne, PA 19087 Contact: (215)676-2334'
- Brooklyn, NY: NYC medical weight loss, sleep and medspa: 2632 E 21st St., Suite L2, Brooklyn, NY 11235 Contact: (718)946-5500
- Cherry Hill, NJ: (Coming soon), tele visits available. Location: 140 E Evesham Rd, Cherry Hill, NJ 08003 Contact:(215)676-2334'
- Links: Weight loss | Sleep medicine | Medical spa | IV nutrition | Success stories |
- Diet pills: Phentermine, Phen/Topiramate, Wegovy, Saxenda, Mounjaro, Contrave, Plenity, Diethylpropion, Phendimetrazine
- Resources: W8MD diet | Keto diet guide | Free Ebook | 12 Ways to lose weight quickly | 8 Amazing Weeks
This is a short summary article. For quality control, we do not encourage or allow strangers to edit the content.